Compare KNDI & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KNDI | QNCX |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.7M | 139.2M |
| IPO Year | N/A | 2019 |
| Metric | KNDI | QNCX |
|---|---|---|
| Price | $0.96 | $4.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 101.8K | ★ 1.1M |
| Earning Date | 11-19-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $104,035,613.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.89 | $0.72 |
| 52 Week High | $1.81 | $4.30 |
| Indicator | KNDI | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 38.06 | 80.98 |
| Support Level | $0.89 | $2.92 |
| Resistance Level | $0.95 | $3.73 |
| Average True Range (ATR) | 0.04 | 0.39 |
| MACD | 0.00 | 0.16 |
| Stochastic Oscillator | 46.43 | 88.93 |
Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.